A total of 60 breakthrough pain patients with bone metastases were randomly divided to 3 groups : group A ( pregabalin combined with intrathecal sufentanil infusion group , n = 20 ) , group B ( placebo combined with intrathecal sufentanil infusion group , n = 20 ) and group C ( oral morphine sulfate controlled-release tablet group , n = 20 ) .